ACCME addresses conflict of interest

Share this article:
Peer-reviewed continuing medical education may become standard under a guidance issued this week that was welcomed by CME providers.
The Accreditation Council for Continuing Medical Education (ACCME) suggested peer reviews as a means of resolving potential conflicts of interest by physicians presenting CME that contained information on drugs made by companies from which they have accepted honoraria. The prompt came in a supplement to the revised Standards for Commercial Support, which advised: "'Peer review' of CME is often already in place and is a mechanism to resolve conflict of interest." Additionally, the provider must ensure that CME references the "best available evidence," the ACCME said in an Oct. 20 document entitled, "Additional Questions and Answers regarding the Updated 2004 Standards for Commercial Support."
CME providers and supporters were alarmed by a previous backgrounder issued by the ACCME, which many interpreted as indicating that faculty with potential conflicts of interest could not discuss their own clinical experience and would be limited to reciting previously published research data. Such a restriction would have driven many of the best CME speakers from the stage, said providers. 
"These two processes provide a roadmap that will allow for the development of policies that will meet the objectives of ACCME while including individuals that may have conflicts," said Marty Cearnal, chief strategy officer for Thomson Medical Education and an early proponent of peer reviews as a means of resolving potential conflicts.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.